The introduction of Rho-kinase (ROCK) inhibitors represents an important advance in the medical management of glaucoma. By targeting the trabecular meshwork to enhance conventional outflow, these agents provide a novel mechanism distinct from existing therapies. With NICE approval of ripasudil/netarsudil, ROCK inhibitors are now accessible in the UK, offering clinicians an additional tool for patients who require further intraocular pressure reduction or for whom traditional treatments are insufficient. This session will review the pharmacological basis of ROCK inhibition, summarise clinical trial data, and discuss real-world considerations for prescribing in practice. Particular emphasis will be placed on efficacy, safety, and tolerability, alongside guidance on patient selection and integration into treatment algorithms.

Learning outcomes:

• Practitioners will gain an evidence-based understanding of the role ROCK inhibitors can play in improving glaucoma outcomes within the evolving therapeutic landscape
• Practitioners will learn how to apply practical and communication strategies for prescribing ROCK inhibitors, including patient selection and side-effect management